Medical Affairs leaders want to be more effective and valuable. They want to secure their seat at the table and influence decisions, impact company performance, and deliver better patient outcomes. To do this, they need to understand the “big picture” of the business and grasp how their decisions and actions contribute to long-term profitability and growth.
This MAPS podcast introduces listeners to social listening to gather insights and discusses implementation, value and technologies.
This Webinar provides perspectives on the evolving role of Digital Opinion Leaders in medical education and shares approaches for identifying, monitoring and engaging them in a compliant manor with relevant examples.
Organizations should take a strategic approach to digital health solutions and also treat them with the same level of rigor applied to traditional therapies. Within the industry, the consensus is that it is a case of when, not if, digital health solutions become the norm.
In “How to Reframe Strategy and Compete on Outcomes,” John Singer, Global Head of Health Industry Strategy, Innovation and Technology at Wipro, elaborates on why Medical Affairs need to drive “big design” thinking to create value in the new outcomes-based healthcare world.
Here we decode self-awareness – the best approach to self-analysis to avoid being trapped looking in the rear-view mirror – and how to find and fix your blindspots.
In My Journey: The Rise & Rise of Medical, Dr. Ameet Nathwani discusses the need to define and measure our contribution, and why we need to join together as a community to shape the future of healthcare.
In “Digital Health: The Road Ahead for Medical Affairs,” CMO and Head of Medical Affairs & Pharmacovigilance at Bayer, Mike Devoy discusses Medical Affairs’ unique understanding of how value can be created and delivered, and the key role it plays in developing the evidence and solutions around that value in collaboration with internal and external partners.
Part 2 of this series will discuss statistical analysis in clinical trials including null/alternative hypotheses; statistical assumptions (type I error, significance level, type II error, statistical power); hypothesis testing; Statistics used in RCTs, including type of outcome measures, analysis of time-to-event variables (plotting and interpretation of Kaplan-Meier curves).
Early Access includes a variety of programs by which pharmaceutical companies make investigational therapies available to patients with life-threatening diseases. These patients have either exhausted available treatments or have no approved options. This presentation will review the processes and procedures to consider in the implementation of an Early Access Program and explore the opportunities and challenges posed therein.